Oral Urea Tablet Formulation for Hyponatremia
Unfortunately, oral urea for hyponatremia is not available in tablet form—it is only manufactured as a powder or liquid formulation that must be dissolved and taken by mouth, typically 15-30 grams per dose mixed with water or juice.
Current Formulation Reality
The FDA-approved oral urea product available in the United States since 2016 comes as a powder that requires dissolution before administration 1, 2. The evidence base consistently describes urea being administered as:
- Powder dissolved in liquid (100-150 mL of water, juice, or normal saline) 3
- Typical dosing: 15-30 grams per dose, 1-2 times daily 4, 5, 6
- Not manufactured as tablets for systemic hyponatremia treatment
Important Distinction: Topical vs. Oral Urea
The FDA drug label information provided 7 describes topical urea cream (20%) for dermatologic use—this is completely different from oral urea for hyponatremia and should not be confused. The topical formulation is for external use only and works by dissolving intercellular matrix in skin 7.
Why This Matters Clinically
Your patient's current regimen of 15 grams twice daily is appropriate and evidence-based 5, 6. The most recent high-quality studies demonstrate:
- Effectiveness: Urea increases sodium from baseline ~124-126 to ~130-134 mmol/L within 6-8 days 5, 6
- Safety profile: Lower overcorrection rates (3.2%) compared to tolvaptan (10.8%) 6
- Cost advantage: Dramatically less expensive than vaptans (€12 vs €468) 6
Practical Solutions for Administration
Since tablets are not available, consider these strategies to improve tolerability:
- Mix with flavored beverages (juice, flavored water) to mask the bitter taste
- Chill the mixture before administration
- Take with meals (as currently prescribed) to improve palatability
- Divide into smaller volumes if the patient finds the volume difficult
Common Pitfall to Avoid
Do not attempt to compound urea into tablets or capsules without pharmaceutical guidance—the hygroscopic nature of urea and required dosing accuracy make this problematic. The powder formulation, while less convenient, ensures proper dissolution and absorption.
Alternative Consideration
If palatability remains a significant barrier despite optimization strategies, tolvaptan is the only tablet alternative, but it comes with substantially higher cost, more frequent overcorrection risk, and requires closer monitoring 6, 8. Given that urea achieves similar sodium normalization rates (79.7% vs 78.0%) with better safety margins 6, optimizing the current powder formulation is preferable to switching therapies.
The 2024 European guidelines specifically endorse oral urea as "very effective and safe treatment" for SIADH, supporting continuation of the current approach 9.